.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
Citi
Dow
Deloitte
Moodys
Covington
Queensland Health
Daiichi Sankyo
UBS

Generated: December 13, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,544,559

« Back to Dashboard

Claims for Patent: 6,544,559

Title: Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Abstract:Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.
Inventor(s): Mesens; Jean (Wechelderzande, BE), Rickey; Michael E. (Loveland, OH), Atkins; Thomas J. (York, PA)
Assignee: Alkermes Controlled Therapeutics Inc. II (Cambridge, MA) Janssen Parmaceutica (Beerse, BE)
Application Number:10/058,072
Patent Claims: 1. A sustained-release microparticle composition, comprising: a first microparticle comprising a first active agent and a first biodegradable and biocompatible polymeric matrix, wherein said first active agent is selected from the group consisting of risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing, and wherein said first microparticle has a first rate of release of said active agent; and a second microparticle comprising a second active agent and a second biodegradable and biocompatible polymeric matrix, wherein said second microparticle has a second rate of release of said active agent different from said first rate of release.

2. The sustained-release microparticle composition of claim 1, wherein said second active agent is the same as said first active agent.

3. The sustained-release microparticle composition of claim 1, wherein said second active agent is selected from the group consisting of risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cerilliant
Cipla
Boehringer Ingelheim
Dow
Farmers Insurance
Chinese Patent Office
Federal Trade Commission
Accenture
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot